| abstract |
The present invention provides a method of identifying a subject having cancer, such as lung cancer, by analyzing the expression level of one or more NRF2 splice variants or NRF2 target genes. The invention also provides a method of treating cancer in a subject with an NRF2 pathway antagonist, wherein the subject expresses one or more NRF2 splice variants or overexpresses one or more NRF2 target genes. [Selection figure] None |